Debt-free Balance SheetA debt-free balance sheet materially lowers near-term solvency risk and preserves financial flexibility. For a pre-commercial medtech developer, absence of debt lets management prioritize R&D, regulatory milestones and partnerships without servicing interest, improving survival odds over the next several months.

Substantial Equity BufferMeaningful equity (~SEK 75.8M) provides a capital cushion to absorb operational losses and fund near-term programs. That buffer reduces immediate pressure to secure dilutive financing, supporting continuity of development and allowing more time to reach commercialization or secure strategic partners.

Contained Cash Burn TrajectoryOperating cash flow is negative but described as not accelerating; stable cash burn implies disciplined cost control and more predictable runway. For investors, a contained burn rate lowers the cadence and urgency of external funding needs, improving the company's ability to execute clinical and regulatory plans.

Bears Say

No Meaningful RevenueEffectively zero revenue across multiple years signals the business is still pre-commercial and lacks product-market traction. Without sales, the company cannot self-fund growth; this structural gap raises dependency on financing or partnerships and lengthens the path to sustainable margins.

Persistent Losses And Negative Cash FlowOngoing net losses (~SEK 11M in 2025) and negative operating cash flow are structural drains on equity and limit reinvestment capacity. Continued losses increase the probability of future dilution or constrained investment into commercialization, raising execution and financing risk over the medium term.

Very Small WorkforceA seven-person team constrains internal capability for clinical trials, regulatory submissions and commercial development. Limited scale increases reliance on partners or contractors, which can slow timelines, add coordination risk, and raise long-term execution uncertainty unless staffing or strategic alliances scale.

Neola Medical AB News

Neola Medical’s Pivotal Study: A Game Changer in Neonatal Lung Monitoring?

Neola Medical AB (($SE:NEOLA)) announced an update on their ongoing clinical study. Study Overview: Neola Medical AB is...

4M ago

NEOLA

NEOLA FAQ

What was Neola Medical AB’s price range in the past 12 months?

Neola Medical AB lowest stock price was kr0.60 and its highest was kr3.04 in the past 12 months.

What is Neola Medical AB’s market cap?

Neola Medical AB’s market cap is kr58.62M.

When is Neola Medical AB’s upcoming earnings report date?

Neola Medical AB’s upcoming earnings report date is May 27, 2026 which is in 97 days.

How were Neola Medical AB’s earnings last quarter?

Neola Medical AB released its earnings results on Feb 12, 2026. The company reported -kr0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.034.

Is Neola Medical AB overvalued?

According to Wall Street analysts Neola Medical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neola Medical AB pay dividends?

Neola Medical AB does not currently pay dividends.

What is Neola Medical AB’s EPS estimate?

Neola Medical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neola Medical AB have?

Neola Medical AB has 77,950,230 shares outstanding.

What happened to Neola Medical AB’s price movement after its last earnings report?

Neola Medical AB reported an EPS of -kr0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.267%.

Which hedge fund is a major shareholder of Neola Medical AB?

Currently, no hedge funds are holding shares in SE:NEOLA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Neola Medical AB

Neola Medical AB (publ) develops medical equipment for continuous monitoring of the lungs of premature babies. It offers neonatal intensive care with NEOLA, a medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. NEOLA provides intensive care and healthier lives for preterm born infants. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.